Physician profile
Lea Tripodi
NPI 1871230573
$10,346.39
in general payments reported to CMS, 2019-2025
29 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,081 · 2023: $4,487 · 2024: $3,388 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,091 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,090.83 |
| Education | $174.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,457.16 | 2022-2025 | |
| Amgen INC. | $1,236.23 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Astrazeneca Pharmaceuticals LP | $881.53 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $824.37 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $655.00 | 2023-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $566.75 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $501.31 | 2022-2025 | |
| Genentech USA, INC. | $418.29 | 2023-2025 | Actemra, Rituxan, Gazyva |
| Lilly USA, LLC | $403.88 | 2022-2024 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $355.76 | 2022-2023 | Krystexxa |
| Pfizer INC. | $300.93 | 2022-2023 | |
| Glaxosmithkline, LLC. | $284.80 | 2023-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.00 | 2022-2024 | Cyltezo, Ofev |
| Sandoz INC. | $168.17 | 2023-2024 | Hyrimoz |
| Radius Health, INC. | $165.98 | 2023-2025 | Tymlos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $143.41 | 2022-2025 | Orencia, Sotyktu |
| Organon LLC | $136.66 | 2022-2025 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $117.06 | 2023-2024 | Idacio |
| Genzyme Corporation | $96.99 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $71.82 | 2023-2024 | Ultomiris |
| Actelion Pharmaceuticals US, INC. | $60.50 | 2024 | Opsumit, Uptravi |
| Aurinia Pharma U.S., INC. | $59.82 | 2023-2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $59.29 | 2023-2024 | Hyqvia |
| Kiniksa Pharmaceuticals International, Plc | $52.52 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $49.58 | 2022-2023 | Arcalyst |
| Octapharma USA, INC. | $34.84 | 2025 | Octagam Immune Globulin (Human) |
| Sobi, INC | $34.53 | 2022-2024 | |
| Biocon Biologics INC | $20.65 | 2024 | Hulio |
| Invivyd INC | $18.56 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Tripodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.